TTOO markets a medical device that assesses blood samples for COV-2, Sepsis as well as other infectious agents.
Before the scamdemic, TTOO was a struggling medical device maker hoping to improve the standard of care for emergency sepsis cases. It looked like Jewmerican economics would prevail and that hospitals would continue to use broad spectrum antibiotics to treat emergency sepsis patients and ask important questions later (if ever). Let's not get in to the Sackler Opioid Epidemic. Keen observers of Western Civilization since Tacitus have known that these filth will undermine any good idea to weaken the host population and push the the financialization of every-day life. So, it's not surprising that minimizing antibiotic resistance by implementing rapid sepsis diagnosis was not looking viable.
One of the few positive outcomes of this Covid New World OP is that the TTOO device turned out to be an excellent tool for rapid Covid diagnosis in the hospital setting. After hospitals bought the TTOO device for Covid, rapid Sepsis testing and other follow-on tests became economically viable.
Q3/20 Revs increased 213% YoY. More importantly, management projects that device placements will nearly double from H-1/20 to H-2/20. Positive cash flow is now possible by the end of Q4/20
I believe there will be a run up into late February earnings and I have already begun to accumulate in anticipation of that earnings report.
